Start Your Free Portfolio Tracker Today
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
The European Commission recently approved
Bayer’s ( BAYRY - Analyst Report) Stivarga (regorafenib) for the treatment of adults suffering from metastatic colorectal cancer (mCRC) whose disease has progressed even after treatment with standard drugs.
The EU approval of Stivarga did not come as a surprise as, in Jun 2013, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) provided a positive opinion on the approval of Stivarga in the mCRC indication.
The European approval of Stivarga was based on positive results from Bayer’s phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) study. Results from the study revealed that overall survival and progression-free survival improved in patients who were treated with Stivarga plus best supportive care.
Stivarga is already available in the U.S. for treating patients suffering from mCRC, whose disease progressed even after treatment with standard drugs. Stivarga is also approved in Japan for the same indication.
Apart from the mCRC indication, the drug is also approved for the treatment of patients suffering from locally advanced, metastatic gastrointestinal stromal tumor (GIST) in the U.S. and Japan besides several other countries.
Stivarga sales in the U.S. for the second quarter of 2013 came in at €47 million. The EU approval of the drug is expected to boost its sales in the coming quarters.
We note that the drug is co-promoted by Bayer and Onyx Pharmaceuticals, Inc. in the U.S. Onyx receives royalty payments from Bayer on all global net sales of Stivarga as per the agreement inked in 2011.
Bayer presently carries a Zacks Rank #3 (Hold). Currently, companies like Actelion Ltd. ( ALIOF - Snapshot Report) and Biogen Idec Inc. ( BIIB - Analyst Report) look well positioned in the pharma space with a Zacks Rank #1 (Strong Buy).